Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab

Authors:
  • ERE. Roddy
    E. Roddy
  • PCP. A. Courtney
    P. A. Courtney
  • AMA. Morris
    A. Morris

Abstract
SIR, The observed elevation of soluble tumour necrosis factor‐alpha (TNFα) receptors in patients with dermatomyositis [1] suggests a possible therapeutic role for biological therapies directed against TNFα. We report a patient with refractory dermatomyositis, who became persistently unwell following treatment with infliximab and subsequently developed non‐Hodgkin's lymphoma.